New York A07920 requires insurance carriers and health plans to cover abuse-deterrent opioid medications.

New York A07920 amends the insurance law to mandate that insurance carriers and health plans include at least one abuse-deterrent opioid analgesic drug product on their formularies. This provision aims to combat opioid abuse by ensuring access to FDA-approved abuse-deterrent technology. The bill prohibits increasing patient cost-sharing or disincentives for prescribers or dispensers to comply with this requirement. Additionally, it ensures that prior-authorization requirements or other utilization review measures do not mandate the use of non-abuse-deterrent opioid products.

New York A07920 requires insurance carriers and health plans to cover abuse-deterrent opioid medications.

New York A07920 amends the insurance law to mandate that insurance carriers and health plans include at least one abuse-deterrent opioid analgesic drug product on their formularies. This provision aims to combat opioid abuse by ensuring access to FDA-approved abuse-deterrent technology. The bill prohibits increasing patient cost-sharing or disincentives for prescribers or dispensers to comply with this requirement. Additionally, it ensures that prior-authorization requirements or other utilization review measures do not mandate the use of non-abuse-deterrent opioid products.